Effect of Sitagliptin on Postprandial Lipoprotein Metabolism
NCT ID: NCT00939939
Last Updated: 2011-06-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE4
3 participants
INTERVENTIONAL
2010-03-31
2011-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Impact of Sitagliptin on Cardiovascular Exercise Performance in Type 2 Diabetes
NCT01951339
Antidiabetic Effects of Adding a DPP-4 Inhibitor to Pre-Existing Treatment With an Incretin Mimetic in Patients With T2D
NCT01937598
Sitagliptin Comparative Study in Patients With Type 2 Diabetes (0431-049)
NCT00449930
Effect of Sitagliptin on Incretin Effect in Patients With Type 2 Diabetes Mellitus
NCT00551590
Sitagliptin Mechanism of Action Study in Patients With Type 2 Diabetes Mellitus (0431-059)
NCT00704132
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
sitagliptin
sitagliptin
sitagliptin 100 mg/d for 10 weeks
glimepirid
glimepiride
glimepiride 1 mg/d for 10 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
sitagliptin
sitagliptin 100 mg/d for 10 weeks
glimepiride
glimepiride 1 mg/d for 10 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* dietary therapy
Exclusion Criteria
* anti-hyperglycemic drug therapy
19 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ludwig-Maximilians - University of Munich
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Med. Dept. 2 University Munich
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medical Dept. 2, Grosshadern, University Munich
Munich, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KP MSD 01-08
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.